Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016
The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.
Overview
Eli Lilly (NYSE:LLY) has been a tremendous growth stock over the years. But thus far in 2026, it's been a fairly underwhelming buy. As of Monday's close, it was up around 8%. While that's a decent return, it trails the S&P 500, which is up by 13%. The stock is on track for its worst performance since 2016, which is the last time it failed to deliver double-digit returns. That year, it declined by nearly 13%.
Is this a sign that the growth stock has run out of room to rise higher?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.